Survival and safety of exemestane versus tamoxifen after 2–3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial
R. Charles Coombes(Hammersmith Hospital), Lucy Kilburn(Institute of Cancer Research), CF Snowdon(Hammersmith Hospital), Robert Paridaens(Universitair Ziekenhuis Leuven), RE Coleman(Weston Park Cancer Centre), SE Jones(Texas Oncology), Jacek Jassem(Gdańsk Medical University), CJH van de Velde(Leiden University Medical Center), T. Delozier(Centre François Baclesse), Isabel Álvarez, Lucia Del Mastro, Olaf Ortmann(University of Regensburg), K. Diedrich(University of Lübeck), AS Coates(International Breast Cancer Study Group), Emilio Bajetta(Fondazione IRCCS Istituto Nazionale dei Tumori), Holmberg Sb(Sahlgrenska University Hospital), David Dodwell, E. Mickiewicz, J. Andersen(Aarhus University Hospital), Per Eystein Lønning(University of Bergen), Giorgio Cocconi(University of Parma), John Forbes(Breast Cancer Trials), M. Castiglione(International Breast Cancer Study Group), N Stuart(Ysbyty Gwynedd Hospital NHS Trust), A. Stewart(The Christie Hospital), Lesley Fallowfield(University of Sussex), Gianfilippo Bertelli(Singleton Hospital), Emma Hall(Institute of Cancer Research), Richard Bogle(Imperial College London), M. Carpentieri(Pfizer (Italy)), E Colajori(Pfizer (Italy)), Milayna Subar(Pfizer (United States)), Elizabeth Ireland(Institute of Cancer Research), Judith M. Bliss(Institute of Cancer Research)
Cited by 908
Abstract
Related Papers
No related papers found
Powered by citation graph analysis